Drug Metabolism and Bioanalysis Letters publishes letters, original research articles, mini-reviews, thematic issues based on mini-reviews and letters, commentaries, technical notes and drug clinical trial studies on major advances in all areas of drug metabolism and bioanalysis.
In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; bioactivation; recent developments for the identification of drug metabolites, reactive intermediate and glutathione conjugates. LC/MS and other key detection methods, including ligand binding assays, sample preparation, chromatography and separation sciences, method development and validation with applications in drug and metabolite assays, pharmacokinetic/toxicokinetic assays, biomarker assays, immunogenicity assays, diagnostic assays.
Zhiyang Zhao Alliance Pharma Malvern, PA (USA) Biography
Biography of Zhiyang Zhao
Zhiyang Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Tech, Blacksburg, Virginia, USA. Dr. Zhao’s biopharmaceutical/pharmaceutical work experience encompasses over 25 years of research in metabolic and pharmacokinetic properties of compounds for drug discovery and development at Pfizer, GlaxoSmithKline and Amgen. Currently, Dr. Zhao serves as Chief Scientific Officer (CSO) at Alliance Pharma, Inc. and is appointed as an adjunct professor at the School of Pharmacy, the University of North Carolina at Chapel Hill. Dr. Zhao has published over 50 peer-reviewed original research papers and patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology.